{"id":"NCT03091673","sponsor":"Xeris Pharmaceuticals","briefTitle":"Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients","officialTitle":"A Phase 3 Study to Evaluate the Glucose Response of G-Pen (Glucagon Injection) in Pediatric Patients With Type 1 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-27","primaryCompletion":"2017-09-07","completion":"2017-09-27","firstPosted":"2017-03-27","resultsPosted":"2018-11-16","lastUpdate":"2018-12-11"},"enrollment":31,"design":{"allocation":"NON_RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"Glucagon","otherNames":["G-Pen (glucagon injection)"]}],"arms":[{"label":"G-Pen (glucagon injection) 0.5 mg","type":"EXPERIMENTAL"},{"label":"G-Pen (glucagon injection) 1.0 mg","type":"EXPERIMENTAL"}],"summary":"This is a sequential efficacy and safety study in pediatric patients with type 1 diabetes. Subjects will be administered insulin to induce a low normal glycemic state and will then receive an age-appropriate dose of G-Pen (glucagon injection) in a clinical research center (CRC) or comparable setting.","primaryOutcome":{"measure":"Change in Plasma Glucose","timeFrame":"0-30 minutes","effectByArm":[{"arm":"Subjects 2 to <6 Years of Age","deltaMin":81.4,"sd":18.3},{"arm":"Subjects 6 to <12 Years of Age","deltaMin":84.2,"sd":25.3},{"arm":"Subjects 12 to <18 Years of Age","deltaMin":54,"sd":27.3}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":14},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":["Nausea","Hypoglycemia","Vomiting","Hyperglycemia","Headache"]}}